This title appears in the Scientific Report :
2010
Please use the identifier:
http://dx.doi.org/10.1021/cn100057j in citations.
Oral Treatment with the D-Enantiomeric Peptide D3 Improves Pathology and Behavior of Alzheimers disease Transgenic Mice
Oral Treatment with the D-Enantiomeric Peptide D3 Improves Pathology and Behavior of Alzheimers disease Transgenic Mice
Several lines of evidence suggest that the amyloid-β-peptide (Aβ) plays a central role in the pathogenesis of Alzheimer's disease (AD). Not only Aβ fibrils but also small soluble Aβ oligomers in particular are suspected to be the major toxic species responsible for disease development and progr...
Saved in:
Personal Name(s): | Funke, S. A. |
---|---|
van Groen, T. / Kadish, I. / Bartnik, D. / Nagel-Steger, L. / Brener, O. / Sehl, T. / Batra-Safferling, R. / Moriscot, C. / Schoehn, G. / Horn, A.H.C. / Müller-Schiffmann, A. / Korth, C. / Sticht, H. / Willbold, D. | |
Contributing Institute: |
Strukturbiochemie; ISB-3 |
Published in: | ACS chemical neuroscience, 1 (2010) S. 639 - 648 |
Imprint: |
Washington, DC
Soc.
2010
|
Physical Description: |
639 - 648 |
DOI: |
10.1021/cn100057j |
PubMed ID: |
22778851 |
Document Type: |
Journal Article |
Research Program: |
BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung Funktion und Dysfunktion des Nervensystems |
Series Title: |
ACS Chemical Neuroscience
1 |
Subject (ZB): | |
Publikationsportal JuSER |
LEADER | 06037nam a2200997 a 4500 | ||
---|---|---|---|
001 | 12404 | ||
005 | 20200402205927.0 | ||
700 | 1 | |0 P:(DE-HGF)0 |a van Groen, T. |b 1 | |
700 | 1 | |0 P:(DE-HGF)0 |a Kadish, I. |b 2 | |
700 | 1 | |0 P:(DE-Juel1)VDB65461 |a Bartnik, D. |b 3 |u FZJ | |
700 | 1 | |0 P:(DE-Juel1)VDB72731 |a Nagel-Steger, L. |b 4 |u FZJ | |
700 | 1 | |0 P:(DE-Juel1)VDB89561 |a Brener, O. |b 5 |u FZJ | |
700 | 1 | |0 P:(DE-Juel1)VDB86041 |a Sehl, T. |b 6 |u FZJ | |
700 | 1 | |0 P:(DE-Juel1)VDB58515 |a Batra-Safferling, R. |b 7 |u FZJ | |
700 | 1 | |0 P:(DE-HGF)0 |a Moriscot, C. |b 8 | |
700 | 1 | |0 P:(DE-HGF)0 |a Schoehn, G. |b 9 | |
700 | 1 | |0 P:(DE-HGF)0 |a Horn, A.H.C. |b 10 | |
700 | 1 | |0 P:(DE-HGF)0 |a Müller-Schiffmann, A. |b 11 | |
700 | 1 | |0 P:(DE-HGF)0 |a Korth, C. |b 12 | |
700 | 1 | |0 P:(DE-HGF)0 |a Sticht, H. |b 13 | |
700 | 1 | |0 P:(DE-Juel1)132029 |a Willbold, D. |b 14 |u FZJ | |
856 | 7 | |2 Pubmed Central |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368690 | |
909 | C | O | |o oai:juser.fz-juelich.de:12404 |p VDB |
970 | |a VDB:(DE-Juel1)124020 | ||
980 | |a VDB | ||
980 | |a ConvertedRecord | ||
980 | |a journal | ||
980 | |a I:(DE-Juel1)ICS-6-20110106 | ||
980 | |a UNRESTRICTED | ||
520 | |a Several lines of evidence suggest that the amyloid-β-peptide (Aβ) plays a central role in the pathogenesis of Alzheimer's disease (AD). Not only Aβ fibrils but also small soluble Aβ oligomers in particular are suspected to be the major toxic species responsible for disease development and progression. The present study reports on in vitro and in vivo properties of the Aβ targeting d-enantiomeric amino acid peptide D3. We show that next to plaque load and inflammation reduction, oral application of the peptide improved the cognitive performance of AD transgenic mice. In addition, we provide in vitro data elucidating the potential mechanism underlying the observed in vivo activity of D3. These data suggest that D3 precipitates toxic Aβ species and converts them into nonamyloidogenic, nonfibrillar, and nontoxic aggregates without increasing the concentration of monomeric Aβ. Thus, D3 exerts an interesting and novel mechanism of action that abolishes toxic Aβ oligomers and thereby supports their decisive role in AD development and progression. | ||
653 | 2 | 0 | |2 Author |a Mirror image phage display |
653 | 2 | 0 | |2 Author |a D-enantiomeric peptide |
653 | 2 | 0 | |2 Author |a Alzheimer's disease |
653 | 2 | 0 | |2 Author |a oligomers |
653 | 2 | 0 | |2 Author |a drugs |
650 | 7 | |2 WoSType |a J | |
915 | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed | ||
914 | 1 | |y 2010 | |
500 | |a This work has been supported by a grant from Volkswagen-Stiftung to D.W., C.K., and H.S. (I/82 649). Support from the "Prasidentenfond der Helmholtzgemeinschaft" (HGF, "Virtual Institute of Structural Biology") to D.W. is acknowledged. C.M. was supported by a DGCIS grant (French state). The electron microscopy facility used for this work is part of the Partnership for Structural Biology (PSB). Part of this research was supported by P30 NS47466. I.K. and T.v.G have been supported by 5P50 AG16582-10. | ||
773 | |0 PERI:(DE-600)2528493-9 |a 10.1021/cn100057j |g Vol. 1, p. 639 - 648 |p 639 - 648 |q 1<639 - 648 |t ACS chemical neuroscience |v 1 |x 1948-7193 |y 2010 | ||
300 | |a 639 - 648 | ||
082 | |a 540 | ||
440 | 0 | |0 23262 |a ACS Chemical Neuroscience |v 1 |x 1948-7193 |y 9 | |
588 | |a Dataset connected to Web of Science, Pubmed | ||
084 | |2 WoS |a Biochemistry & Molecular Biology | ||
084 | |2 WoS |a Chemistry, Medicinal | ||
084 | |2 WoS |a Neurosciences | ||
245 | |a Oral Treatment with the D-Enantiomeric Peptide D3 Improves Pathology and Behavior of Alzheimers disease Transgenic Mice | ||
024 | 7 | |2 pmid |a pmid:22778851 | |
024 | 7 | |2 pmc |a pmc:PMC3368690 | |
024 | 7 | |2 DOI |a 10.1021/cn100057j | |
024 | 7 | |2 WOS |a WOS:000281891700007 | |
024 | 7 | |a altmetric:21805124 |2 altmetric | |
037 | |a PreJuSER-12404 | ||
260 | |a Washington, DC |b Soc. |c 2010 | ||
100 | 1 | |0 P:(DE-Juel1)VDB65869 |a Funke, S. A. |b 0 |u FZJ | |
041 | |a eng | ||
913 | 1 | |0 G:(DE-Juel1)FUEK409 |a DE-HGF |b Gesundheit |k P33 |l Funktion und Dysfunktion des Nervensystems |v Funktion und Dysfunktion des Nervensystems |x 0 | |
913 | 1 | |0 G:(DE-Juel1)FUEK505 |a DE-HGF |b Schlüsseltechnologien |k P45 |l Biologische Informationsverarbeitung |v BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |x 1 | |
913 | 2 | |0 G:(DE-HGF)POF3-553 |1 G:(DE-HGF)POF3-550 |2 G:(DE-HGF)POF3-500 |a DE-HGF |b Key Technologies |l BioSoft Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |v Physical Basis of Diseases |x 0 | |
536 | |a BioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung |0 G:(DE-Juel1)FUEK505 |2 G:(DE-HGF) |c P45 |x 1 | ||
536 | |a Funktion und Dysfunktion des Nervensystems |0 G:(DE-Juel1)FUEK409 |2 G:(DE-HGF) |c P33 |x 0 | ||
336 | |a ARTICLE |2 BibTeX | ||
336 | |a Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) |0 0 |2 EndNote | ||
336 | |a Output Types/Journal article |2 DataCite | ||
336 | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) | ||
336 | |a article |2 DRIVER | ||
336 | |a JOURNAL_ARTICLE |2 ORCID | ||
981 | |a I:(DE-Juel1)IBI-7-20200312 | ||
920 | |k Strukturbiochemie; ISB-3 |0 I:(DE-Juel1)VDB942 |d 31.12.2010 |g ISB |l Strukturbiochemie |x 0 | ||
981 | |a I:(DE-Juel1)ICS-6-20110106 | ||
991 | |0 P:(DE-HGF)0 |a Schoehn, G. |b 9 | ||
991 | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 14 |u FZJ | ||
991 | |0 P:(DE-HGF)0 |a Moriscot, C. |b 8 | ||
991 | |0 P:(DE-HGF)0 |a Sticht, H. |b 13 | ||
991 | |a Batra-Safferling, R. |0 P:(DE-Juel1)VDB58515 |b 7 |u FZJ | ||
991 | |0 P:(DE-HGF)0 |a Korth, C. |b 12 | ||
991 | |a Sehl, T. |0 P:(DE-Juel1)VDB86041 |b 6 |u FZJ | ||
990 | |a Funke, S. A. |0 P:(DE-Juel1)VDB65869 |b 0 |u FZJ | ||
991 | |0 P:(DE-HGF)0 |a Müller-Schiffmann, A. |b 11 | ||
991 | |a Brener, O. |0 P:(DE-Juel1)VDB89561 |b 5 |u FZJ | ||
991 | |0 P:(DE-HGF)0 |a Horn, A.H.C. |b 10 | ||
991 | |a Nagel-Steger, L. |0 P:(DE-Juel1)VDB72731 |b 4 |u FZJ | ||
991 | |a Bartnik, D. |0 P:(DE-Juel1)VDB65461 |b 3 |u FZJ | ||
991 | |0 P:(DE-HGF)0 |a Kadish, I. |b 2 | ||
991 | |0 P:(DE-HGF)0 |a van Groen, T. |b 1 |